More than 35 industry players claim to offer services for the identification, characterization and development >>>...
Drug discovery is challenging and involves several complexities. In order to continue to add new molecules their pipelines, drug developers are opting to outsource such operations to contract research organizations (CROs). Outsourcing of peptides and macrocycle drug discovery has emerged as one of the recent trends in the overall pharmaceutical domain.
To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this link
The USD 1.5 billion (by 2030) financial opportunity within the peptides and macrocycles drug discovery service and platform providers market has been analyzed across the following segments:
Type of peptides
Synthetic peptides
Biologic and recombinant peptides
Type of discovery steps
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape of Service Providers
5. Benchmark Analysis
6. Market Landscape of Platform Providers
7. Company Profiles
8. Partnerships
9. Market Forecast and Opportunity Analysis
10. SWOT Analysis
11. Conclusion
12. Executive Insights
13. Appendix 1: List of Companies and Organizations
14. Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this link
The USD 1.5 billion (by 2030) financial opportunity within the peptides and macrocycles drug discovery service and platform providers market has been analyzed across the following segments:
Type of peptides
Synthetic peptides
Biologic and recombinant peptides
Type of discovery steps
- Target identification and validation
- Hit identification
- Lead generation
- Lead optimization
- Therapeutic Area
- Oncological disorders
- Metabolic disorders
- Cardiovascular disorders
- Infectious diseases
- Urological disorders
- Endocrine disorders
- CNS disorders
- Other diseases
- Company Size
- Small companies
- Mid-sized companies
- Large and very large companies
- Europe
- North America
- Asia-Pacific and the Rest of the World
- Mark I Peterson (CEO, Cyclenium Pharma)
- Jan Hoflack (Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)
- GenScript
- JPT Peptide Technologies
- CPC Scientific
- IRBM
- Creative Peptides
- Pepscan
- Interprotein
- RA Pharmaceuticals
- Pepticom
- PeptiDream
- Creative Biolabs
- MeSCue-Janusys
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape of Service Providers
5. Benchmark Analysis
6. Market Landscape of Platform Providers
7. Company Profiles
8. Partnerships
9. Market Forecast and Opportunity Analysis
10. SWOT Analysis
11. Conclusion
12. Executive Insights
13. Appendix 1: List of Companies and Organizations
14. Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
No comments yet... Be the first to leave a reply! Login here